The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Alnylam Pharmaceuticals Inc shares valued at $4,200,000 were sold by Greenstreet Yvonne on Aug 20 ’24. At $280.00 per share, Greenstreet Yvonne sold 15,000 shares. The insider’s holdings dropped to 73,441 shares worth approximately $21.79 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Greenstreet Yvonne purchased 15,000 shares, netting a total of over 4,200,000 in proceeds.
Before that, Fitzgerald Kevin Joseph had sold 22,025 shares from its account. In a trade valued at $5,968,516, the CSO & EVP, Head of Research traded Alnylam Pharmaceuticals Inc shares for $270.99 each. Upon closing the transaction, the insider’s holdings decreased to 22,025 shares, worth approximately $3.82 million.
As published in their initiating research note from Scotiabank on October 16, 2024, Alnylam Pharmaceuticals Inc [ALNY] has been a Sector outperform. Analysts at Goldman upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid August. As of February 16, 2024, Goldman has decreased its “Buy” rating to a “Neutral” for ALNY. Earlier on February 15, 2024, Wolfe Research initiated its rating. Their recommendation was “a Peer perform” for ALNY stock.
Analyzing ALNY Stock Performance
During the last five days, there has been a surge of approximately 6.51%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 55.03%. Shares of the company reached a 52-week high of $304.39 on 10/17/24 and a 52-week low of $141.98 on 04/25/24. A 50-day SMA is recorded $271.45, while a 200-day SMA reached $201.07. Nevertheless, trading volume fell to 1.21 million shares from 1.26 million shares the previous day.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 294.10, which, if violated, would cause prices to drop to 291.44. In the upper region, resistance lies at 301.90. The next price resistance is at 307.04. RSI (Relative Strength Index) is 70.25 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 16.32, which suggests the price will increase in the coming days. Percent R is at 18.99%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
